GenixPharmaceucticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to support kidney health; and Sucanon, a herbal health supplement to manage blood… Read more
GenixPharmaceucticals Corporation (GENX) - Total Liabilities
Latest total liabilities as of April 2025: CA$1.38 Million CAD
Based on the latest financial reports, GenixPharmaceucticals Corporation (GENX) has total liabilities worth CA$1.38 Million CAD as of April 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GenixPharmaceucticals Corporation - Total Liabilities Trend (2015–2024)
This chart illustrates how GenixPharmaceucticals Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GenixPharmaceucticals Corporation Competitors by Total Liabilities
The table below lists competitors of GenixPharmaceucticals Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MODERNA
STU:0QF
|
Germany | €3.97 Billion |
|
FED INVESTORS-B - Dusseldorf Stock Exchang
DU:3KC
|
Germany | €900.63 Million |
|
Tangiamo Touch Technology AB
ST:TANGI
|
Sweden | Skr14.30 Million |
|
Greenlit Ventures Inc
PINK:GLVT
|
USA | $227.94K |
|
EGRNF
PINK:EGRNF
|
USA | $29.17 Million |
|
US STEEL (USX1.SG)
STU:USX1
|
Germany | €8.96 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down GenixPharmaceucticals Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 33.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GenixPharmaceucticals Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GenixPharmaceucticals Corporation (2015–2024)
The table below shows the annual total liabilities of GenixPharmaceucticals Corporation from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-10-31 | CA$1.23 Million | -9.71% |
| 2023-10-31 | CA$1.36 Million | +29.17% |
| 2022-10-31 | CA$1.05 Million | +39.50% |
| 2021-10-31 | CA$755.19K | +54.16% |
| 2020-10-31 | CA$489.88K | +494.44% |
| 2019-10-31 | CA$82.41K | -24.50% |
| 2018-10-31 | CA$109.15K | -59.99% |
| 2017-10-31 | CA$272.80K | +300.95% |
| 2016-10-31 | CA$68.04K | -38.58% |
| 2015-10-31 | CA$110.78K | -- |